Chronic cutaneous adverse events affected 8% of patients after checkpoint inhibitor therapy in a cohort study, often ...

Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive ...

February 19, 2025, the company was named an Advanced Partner under the X Ads Agency Certification Program by X Corp. Japan K.K. Among all certified advertising agencies, X Corp. Japan K.K. recognizes ...

Discover how one organization is bridging global medical education standards to ensure quality healthcare in the United States and around the ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Prelude Therapeutics Incorporated (Nasdaq: PRLD) has released its 2024 financial results and provided an update on its ...

Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several ...

Jewellery & Gem ASEAN Bangkok 2025 (JGAB 2025), scheduled to take place from April 23-26, 2025, at the Queen Sirikit National ...

Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.